Skip to main content
Open Access Emergency Medicine : OAEM logoLink to Open Access Emergency Medicine : OAEM
. 2024 Jun 25;16:133–144. doi: 10.2147/OAEM.S455159

Electrocardiographic Abnormalities in Patients with Hyperkalemia: A Retrospective Study in an Emergency Department in Colombia

Jaime A Quintero 1,2,3,, Camilo A Medina 1,4,5, Federico Penagos 3,4, Jaime Andres Montesdeoca 3,4, Gildardo Antonio Orozco 1,4, Juan Saavedra-Castrillón 3,4, Julio Diez-Sepulveda 1,3,4
PMCID: PMC11215665  PMID: 38952854

Abstract

Introduction

Hyperkalemia is a prevalent electrolyte disorder related to elevated serum potassium levels, resulting in diverse abnormal electrocardiographic findings and associated clinical signs and symptoms, often necessitating specific treatment. However, in some patients, these abnormal findings may not be present on the electrocardiogram even in elevated serum potassium levels. This study aims to identify electrocardiographic abnormalities related to the severity of hyperkalemia and the clinical outcomes in an emergency department in southwestern Colombia.

Methodology

This is a retrospective cross-sectional descriptive study. We described the electrocardiographic findings, clinical characteristics, treatment, and outcomes related to the degrees of hyperkalemia. The potential association between the severity of hyperkalemia and electrocardiographic findings was evaluated.

Results

A total of 494 patients were included. The median of the potassium level was 6.6 mEq/L. Abnormal electrocardiographic findings were reported in 61.5% of the cases. Mild and severe hyperkalemia groups reported abnormalities in 59.9% and 61.2%, respectively. The most common electrocardiography abnormalities were the peaked T wave 36.2%, followed by wide QRS 83 (16.8%). Only 1.4% of patients had adverse outcomes. The abnormal findings were registered in 61.5%. Mortality was 11.9%. The peaked T wave was the most common finding across different levels of hyperkalemia severity.

Conclusion

High serum potassium levels are related with abnormal ECG. However, patients with different degrees of hyperkalemia could not describe abnormal ECG findings. In a high proportion of patients with renal chronic disease and hyperkalemia, the abnormalities in the ECG could be minimal or absent.

Keywords: hyperkalemia, degree, outcomes, electrocardiographic, ECG, abnormalities

Introduction

Hyperkalemia is a common electrolyte disorder defined as high serum potassium (K+) concentrations1,2 and it can be classified to the serum concentration defined as a serum level of potassium greater than 5.5 mEq/L.3–5 Certain conditions can increase serum potassium concentration, such as chronic kidney disease, diabetes, and medications.6–8

Clinical manifestations are associated with the grade of hyperkalemia. Some symptoms have been described, as a weakness, paresthesia, and muscular fasciculation in the arms and legs are the most common symptoms, followed by paralysis, nausea, vomiting, and diarrhea. In a few cases, the manifestations could be severe like a mimicking Guillain–Barré syndrome.9,10 Dysrhythmias, ventricular fibrillation, and asystole manifestations have been described as electrocardiography manifestations. Nevertheless, the majority of patients with hyperkalemia are asymptomatic.3,11

Electrocardiographic (ECG) abnormalities have been described, such as the presence of peaked T waves, shortened QT interval, prolonged PR intervals, disappearance or flattening of P waves, sinusoidal wave, and in some cases alterations in the cardiac rhythm.11–16 Nevertheless, the literature describes that ECG findings do not directly correlate with high serum potassium levels,17–19 and some patients have reported hyperkalemia without electrocardiographic alterations like patients with chronic kidney disease without ECG changes despite elevated potassium levels.6,20–22

However, in certain instances, this condition can induce electrocardiographic alterations that may pose potential seriousness, necessitating emergent therapy intervention. Some of these employed to rectify potassium levels encompass the utilization of loop diuretics, beta-agonists, polarizing solutions, hemodialysis, insulin, and ion-exchange resins coupled with a membrane stabilizer featuring calcium gluconate for action potential control. The value of early recognition of hyperkalemia using the ECG has been described.23

In our country, only a limited number of case reports have been performed in various contexts. One study described the clinical characteristics of patients with long-term prescriptions for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers despite the absence of electrocardiographic changes.24 Additional case reports have reported the correlation between medication usage and chronic kidney disease. Nevertheless, there is no comprehensive study with a substantial number of patients reported in the country or southwestern Colombia.

This study aimed to describe the abnormal ECG findings related to serum potassium levels and clinical outcomes in an emergency department of southwest from Colombia.

Methods

Design of the Study

A retrospective cross-sectional descriptive study was performed in an emergency department of a high-complexity university hospital between January 2011 and December 2020.

Population

All patients aged ≥18 years attending the emergency department between 2011 and 2020 with a diagnostic of hyperkalemia intra-hospital (serum potassium concentration is ≥5.5 mEq/L) with an electrocardiogram (ECG) close to the report confirming elevated potassium levels and diagnosing hyperkalemia.

Patients with a history of permanent atrial fibrillation, intracardiac device (pacemaker, cardio-synchronizer, or implantable defibrillator), patients with ECG of poor quality that could not be interpreted or no ECG report, undergoing palliative care treatment, or being pregnant were excluded.

Variables Description

Demographic variables, clinical history, physiological variables, laboratory variables upon admission, symptoms related to hyperkalemia, initial and follow-up ECG findings, initiation of anti-hyperkalemic measures (no treatment, monotherapy, and combination therapy), and adverse outcomes such as malignant arrhythmias and cardiac arrest were collected from medical history.

ECG abnormalities were defined as at least one of the following findings: shortened QT interval, peaked T waves, reduction of the amplitude or absence of the P wave, QRS prolongation, prolonged PR interval, loss of sinoatrial conduction with the onset of a wide-complex “sine wave” ventricular rhythm, Brugada phenocopy, or any types of block heart (AV block or bundle branch block).

The classification of hyperkalemia was based in European Resuscitation Council Guideline (ERCG) (endorsed by UK Renal Association): mild hyperkalemia (5.5–5.9 mEq/L), moderate hyperkalemia (6–6.4 mEq /L) and severe hyperkalemia (≥6.5 m mEq/L).25

Statistical Analysis

The Shapiro–Wilk statistical test was used to assess the distribution of the quantitative variables. These variables were described using measures of central tendency and dispersion. The chi-square test was employed to assess the association between the severity of hyperkalemia and electrocardiographic findings. A multivariate analysis was conducted using logistic regression. Abnormal electrocardiographic findings with a p value <0,2 in the bivariate analysis as independent variables. The model was adjusted for confounding variables including age ≥60, sex, cardiac arrest rhythms, and renal chronic disease. The goodness-of-fit of the model was evaluated using the Hosmer–Lemeshow test. The analysis was conducted using StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.

The Biomedical Research Ethics Committee at the University Hospital (Comité de Ética en Investigación Biomédica de la Fundación Valle del Lili) approved this study (Approved No. 280–2021, No. 15 of July 28, 2021). This study adheres to the Helsinki Declaration of Ethical Principles for Medical Research in Human Beings. According to the resolution 8430 of 1993 of the Colombian Ministry of Health, this study did not represent risk and did not require informed consent. This study followed the standards of the STROBE guidelines. The researchers did not expose the patients to biological, psychological, or social risks. Therefore, the ethics committee approved the waiver of informed consent.

Results

A total of 494 patients were included (Figure 1). The median ages were similar among those with mild, moderate, and severe hyperkalemia. The majority of the population were men (57.1%). The most frequent medical history was arterial hypertension (71.7%), followed by chronic kidney disease (63%). The most frequently reported symptom was weakness, followed by nausea/vomiting. Nevertheless, mild and moderate groups were the most common of weakness and respiratory distress. The median serum potassium level was 6.6 mEq/L. The most common cardiac rhythm observed was sinus rhythm. More than half of the cases presented at least one abnormal finding, with a similar distribution across severity groups (Table 1).

Figure 1.

Figure 1

Flowchart.

Table 1.

Demographic and Clinical Characteristics of the Study Population

Variables Available Data Overall, n: 494 Classification of Hyperkalemia
Mild (n: 102) Moderate (n: 122) Severe (n: 270)
Age* 494 63 (48–73) 64.5 (53–74) 65 (52–75) 61 (45–72)
Age ≥60 years 494 318 (64.4%) 93 (91.2%) 78 (63.9%) 147 (54.4%)
Gender
Female 494 212 (42.9%) 48 (47.1%) 58 (47.5%) 106 (39.3%)
Male 494 282 (57.1%) 54 (52.9%) 64 (52.5%) 164 (60.7%)
Background
Hypertension 494 354 (71.7%) 70 (68.6%) 85 (69.7%) 199 (73.7%)
Chronic kidney disease 494 311 (63.0%) 47 (46.1%) 58 (47.5%) 206 (76.3%)
Diabetes 494 173 (35.0%) 37 (36.3%) 51 (41.8%) 85 (31.5%)
Cancer 494 76 (15.4%) 19 (18.6%) 21 (17.2%) 36 (13.3%)
Heart failure 494 62 (12.6%) 10 (9.8%) 13 (10.7%) 39 (14.4%)
Immunosuppression 494 61 (12.4%) 7 (6.9%) 19 (15.6%) 35 (13.0%)
Autoimmune disease 494 36 (7.3%) 3 (2.9%) 10 (8.2%) 23 (8.5%)
Chronic obstructive pulmonary disease 494 27 (5.5%) 6 (5.9%) 9 (7.4%) 12 (4.4%)
Arrhythmias 494 10 (2.0%) 1 (1.0%) 0 9 (3.3%)
Asthma 494 4 (0.8%) 2 (2.0%) 0 2 (0.7%)
Physiological variables
Systolic blood pressure * 494 130 (111–152) 130 (114–147) 132.5 (108–152) 130 (112–154)
Diastolic blood pressure* 494 73 (61–86) 72 (64–85) 72 (58–84) 74.5 (60–88)
Heart rate* 494 83.5 (70–98) 84 (70–98) 85 (70–99) 82 (71–98)
Respiratory rate* 494 18 (17–20) 18 (17–20) 18 (17–20) 18 (17–20)
Arterial saturation* 494 97 (95–98) 97 (95–98) 96 (94–98) 97 (95–99)
Temperature, (C°)* 494 36.2 (36–36.5) 36.2 (36–36.5) 36.1 (36–36.5) 36.2 (36–36.5)
Paraclinical
Creatinine * 443 3.56 (1.9–8.2) 2.6 (1.7–6.6) 2.77 (1.6–5.3) 4.38 (2.5–9.7)
BUN* 470 57.3 (40–78.5) 53 (36.4–68.5) 50.7 (35.3–77.6) 63.1 (42.7–81.6)
Na* 466 136 (133–139) 137 (134–141) 136.9 (132.8–139.9) 135.7 (133–138)
K* 494 6.6 (6.1–7.0) 5.7 (5.6–5.9) 6.2 (6.1–6.3) 6.9 (6.6–7.3)
Mg* 192 2.03 (1.8–2.4) 2.01 (1.6–2.4) 1.92 (1.7–2.2) 2.12 (1.82–2.5)
Ca* 204 8.8 (8.1–9.6) 8.7 (7.6–9.2) 9.2 (8.5–9.8) 8.71 (7.81–9.5)
Cl* 384 101.5 (96.2–107) 102.7 (98–107.2) 101.4 (95.2–106.6) 100.7 (96.2–107)
Glucose* 333 119 (94–158) 129 (90–157) 120.5 (94–170.5) 117 (95–157)
Symptoms related to Hyperkalemia 494 175 (35.4%) 26 (25.5%) 41 (33.6%) 108 (40%)
Weakness 494 105 (21.3%) 18 (17.6%) 20 (16.4%) 67 (24.8%)
Nausea/vomiting 494 51 (10.3%) 6 (5.9%) 11 (9.0%) 34 (12.6%)
Abdominal pain 494 42 (8.5%) 7 (6.9%) 6 (4.9%) 29 (10.7%)
Respiratory distress 494 48 (9.7%) 8 (7.8%) 14 (11.5%) 26 (9.6%)
Slow, weak, or irregular pulse 494 17 (3.4%) 0 5 (4.1%) 12 (4.4%)
Anxiety 494 16 (3.3%) 0 6 (4.9%) 10 (3.7%)
Irritability and restlessness 494 15 (3.0%) 0 3 (2.5%) 12 (4.4%)
Numbness and tingling of the fingertips 494 12 (2.4%) 1 (1%) 1 (0.8%) 10 (3.7%)
Flaccid quadriplegia 494 2 (0.4%) 0 1 (0.8%) 1 (0.3%)
Initial Rhythm
Sinus rhythm 494 416 (84.2%) 74 (72.6%) 106 (86.9%) 236 (87.4%)
Sinus tachycardia 494 34 (6.9%) 13 (12.8%) 6 (4.9%) 15 (5.6%)
Atrial fibrillation 494 16 (3.2%) 6 (5.9%) 3 (2.5%) 7 (2.6%)
Sinus bradycardia 494 12 (2.4%) 3 (2.9%) 3 (2.5%) 6 (2.2%)
Indeterminate rhythm 494 7 (1.4%) 3 (2.9%) 3 (2.5%) 1 (0.4%)
AESP 494 3 (0.6%) 1 (1%) 0 2 (0.7%)
Atrial flutter 494 2 (0.4%) 1 (1%) 1 (0.8%) 0
Idioventricular rhythm 494 1 (0.2%) 0 0 1 (0.4%)
Ventricular tachycardia 494 1 (0.2%) 1 (1%) 0 0
Asystole 494 1 (0.2%) 0 0 1 (0.4%)
Pulseless ventricular tachycardia 494 1 (0.2%) 0 0 1 (0.4%)
Treatment
Insulin / Glucose 494 281 (56.9%) 44 (43.1%) 69 (56.6%) 168 (62.2%)
Loop Diuretics 494 263 (53.2%) 53 (52%) 69 (56.6%) 141 (52.2%)
Beta agonist 494 231 (46.8%) 36 (35.3%) 58 (47.5%) 137 (50.7%)
Calcium salts 494 209 (42.3%) 22 (21.6%) 50 (41%) 137 (50.7%)
Hemodialysis 494 199 (40.3%) 32 (31.4%) 40 (32.8%) 127 (47%)
Ion exchange resins 494 191 (38.7%) 28 (27.4%) 47 (38.5%) 116 (43%)
Sodium bicarbonate 494 144 (29.25) 33 (32.4%) 26 (21.3%) 85 (31.5%)
No treatment 494 9 (1.8%) 3 (2.9%) 3 (2.5%) 3 (1.1%)
Principal diagnostic
Renal diseases 494 172 (34.8% 22 (21.6%) 35 (28.7%) 115 (42.59%)
Infectious diseases 494 86 (17.4%) 21 (20.6%) 18 (14.8%) 47 (17.4%)
Cardiovascular diseases 494 57 (11.5%) 16 (15.7%) 21 (17.2%) 20 (7.4%)
Postoperative 494 47 (9.5%) 14 (13.7%) 14 (11.5%) 19 (7%)
Metabolic diseases 494 37 (7.5%) 4 (3.9%) 10 (8.2%) 23 (8.5%)
Neoplasia 494 32 (6.5%) 7 (6.9%) 9 (7.4%) 16 (5.9%)
Digestive diseases 494 22 (4.4%) 4 (3.9%) 7 (5.7%) 11 (4.1%)
Respiratory diseases 494 12 (2.4%) 3 (2.9%) 3 (2.5%) 56 (2.2%)
Neurological diseases 494 11 (2.2%) 7 (6.9%) 3 (2.5%) 1 (0.4%)
Trauma 494 6 (1.2%) 1 (1%) 1 (0.8%) 4 (1.5%)
Immuno-Rheumatology diseases 494 5 (1.0%) 1 (1%) 1 (0.8%) 3 (1.1%)
Hematological diseases 494 2 (0.4%) 1 (1%) 0 1 (0.4%)
Neuromuscular diseases 494 2 (0.4%) 0 0 2 (0.7%)
Toxicity 494 1 (0.4%) 1 (1%) 0 1 (0.4%)
Urological diseases 494 1 (0.4%) 0 0 1 (0.4%)
Vascular diseases 494 1 (0.4%) 0 0 1 (0.4%)
Abnormal ECG findings 494 304 (61.5%) 57 (55.9%) 78 (63.9%) 169 (62.6%)
Hospitalization days** 494 15.33 (± 20.61) 17.5 (± 26.19) 14.2 (± 18.1) 14.9 (±19.26)
Intra-hospital death 494 59 (11.9%) 16 (15.7%) 14 (11.5%) 29 (10.7%)

Notes: *Median (IQR), **Mean (SD).

Regarding the treatment, the most commonly administered medication was the polarizing solution (insulin/glucose), followed by loop diuretics and beta-agonists (Table 1), and the combined therapy was the most used (Figure 2).

Figure 2.

Figure 2

ECG findings and degrees of hyperkalemia.

The peaked T wave was the most frequently observed abnormality (36.2%), followed by a Wide QRS complex with bizarre morphologies (16.8%), PR interval elongation (13.6%), and block heart (13.2%). Only five patients experienced cardiac arrest (three patients with pulseless electrical activity, one with asystole, and one with pulseless ventricular tachycardia). The moderate hyperkalemia group documented the most frequent abnormal findings. The distribution of hyperkalemia severity groups for each abnormal finding is illustrated in Figure 3. The relationship between ECG abnormalities and the severity of hyperkalemia was documented in all patients (Table 2) and specifically in patients with chronic kidney disease (Table 3). After running the model, the variable for peaked T waves maintains its statistical significance (p≤0.001). This suggests that patients who present this finding have 2.4 times the chance of having moderate-to-severe hyperkalemia compared to patients without this feature. The goodness-of-fit test indicates that the model fits the data (p=0.148) (Table 4).

Figure 3.

Figure 3

Treatment.

Table 2.

Relationship Between Abnormal Electrocardiogram Findings/Demographic Variables and Severity of Hyperkalemia

Variables Mild, n: 102 Moderate, n: 122 Severe, n: 270 P -value
Age ≥ 60
No 9 (8.8%) 44 (36.1%) 123 (45.6%) <0.001
Yes 93 (91.2%) 78 (63.9%) 147 (54.4%)
Gender
Female 48 (47.1%) 58 (47.5%) 106 (39.3%) 0.197
Male 54 (52.9%) 64 (52.5%) 164 (60.7%)
Cardiac arrest rhythms
No 101 (99.0%) 122 (100%) 266 (98.5%) 0.253
Yes 1 (1.0%) 0 4 (1.5%)
Renal chronic disease
No 55 (53.9%) 64 (52.5%) 64 (23.7%) < 0.001
Yes 47 (46.1%) 58 (47.5%) 206 (76.3%)
Diabetes
No 65 (63.7%) 71 (58.2%) 185 (68,5%) 0.134
Yes 37 (36.3%) 51 (41.8%) 85 (31,5%)
Abnormal electrocardiogram findings
No 45 (44,1%) 44 (36.1%) 101 (37.4%) 0.406
Yes 57 (55.9%) 78 (63.9%) 169 (62.6%)
Peaked t wave
No 80 (78.4%) 71 (58.2%) 164 (60.7%) 0.002
Yes 22 (21.6%) 51 (41.8%) 106 (39.3%)
Wide QRS with bizarre morphologies
No 88 (86.3%) 101 (82.8%) 222 (82.8%) 0.641
Yes 14 (13.7%) 21 (17.2%) 48 (17.2%)
Prolonged PR interval
No 91 (89.2%) 105 (86.1%) 231 (85.6%) 0.649
Yes 11 (10.8%) 17 (13.9%) 39 (14.4%)
Heart block
No 85 (83.3%) 105 (86.1%) 239 (88.5%) 0.401
Yes 17 (16.7%) 17 (13.9%) 31 (11.5%)
Widening and flattening of the P wave
No 92 (90.2%) 109 (89.3%) 241 (89.3%) 0.965
Yes 10 (9.8%) 13 (10.7%) 29 (10.7%)
Disappearance of the P wave
No 94 (92.2%) 116 (95.1%) 253 (93.7%) 0.667
Yes 8 (7.8%) 6 (4.9%) 17 (6.3%)
Sinusoidal wave
No 102 (100%) 122 (100%) 266 (98.5%) 0.188
Yes 0 0 4 (1.5%)

Table 3.

Relationship Between Abnormal Electrocardiogram Findings and Severity of Hyperkalemia in Patients with CKD

Variables Mild, n: 47 Moderate, n: 58 Severe, n: 206 P-value
Age ≥ 60
No 3 (6,4%) 22 (37.9) 99 (48.1%) <0.001
Yes 44 (93.6%) 36 (62.1) 107 (51.9%)
Gender
Female 20 (42.6%) 25 (43.1%) 78 (37.9%) 0.197
Male 27 (57.4%) 33 (56.1%) 128 (62.1%)
Abnormal Electrocardiogram Findings
No 18 (38.3%) 22 (37.9%) 76 (36.9%) 0.978
Yes 29 (61.7%) 36 (62.1%) 130 (63.1%)
Peaked t wave
No 34 (72.3%) 35 (60.3%) 124 (60.2%) 0.288
Yes 13 (27.7%) 23 (39.7%) 82 (39.8%)
Wide QRS with bizarre morphologies
No 39 (83%) 47 (81%) 167 (81.1%) 0.953
Yes 8 (17%) 11 (19%) 39 (18.9%)
Prolonged PR interval
No 41 (87.2%) 54 (93.1%) 176 (85.4%) 0.305
Yes 6 (12.8%) 4 (6.9%) 30 (14.6%)
Heart block
No 40 (85.1%) 51 (87.9%) 182 (88.3%) 0.828
Yes 7 (14.9%) 7 (12.1%) 24 (11.7%)
Widening and flattening of the P wave
No 41 (87.2%) 51 (87.9%) 182 (88.3%) 0.977
Yes 6 (12.8%) 7 (12.1%) 24 (11.7%)
Disappearance of the P wave
No 41 (87.2%) 54 (93.1%) 194 (94.2%) 0.246
Yes 6 (12.8%) 4 (6.9%) 12 (5.8%)
Cardiac arrest rhythms
No 47 (100%) 58 (100%) 203 (98.5%) 0.462
Yes 0 0 3 (1.5%)
Sinusoidal wave
No 47 (100%) 58 (100%) 202 (98.1%) 0.356
Yes 0 0 4 (1.9%)

Table 4.

Multivariate Analysis

Variable Odds Ratio p value CI (95%)
Age ≥60 0.123 >0.001 0.588–0.259
Sex 1.517 0.092 0.934–2.464
Diabetes 1.344 0.242 0.818–2.206
Chronic kidney disease 2.082 0.002 1.3–3.335
Peaked t wave 2.355 >0.001 1.36–4,078

Only five patients reported arrest rhythm and the post-discharge mortality rate was 11.9% but decreased with the severity (15.7%, 11.5%, and 10.7%) (Table 5).

Table 5.

Description of Deceased Patients

Mild (n: 16) Moderate (n: 14) Severe (n: 29)
Age by groups
< 60 1 (6.2%) 4 (28.6%) 6 (20.7%)
≥ 60 15 (93.8%) 10 (71.4%) 23 (79.3%)
Principal diagnostic
Cardiovascular diseases 3 (18.8%) 7 (50%) 4 (13.8%)
Digestive diseases 0 0 1 (3.4%)
Infectious diseases 9 (56.3%) 6 (42.9%) 10 (34.5%)
Metabolic diseases 0 0 1 (3.4%)
Neoplasia 1 (6.2%) 0 3 (10.3%)
Neurological diseases 0 0 1 (3.4%)
Trauma 0 0 1 (3.4%)
Renal diseases 2 (12.5%) 1 (7.1%) 7 (24.1%)
Respiratory diseases 1 (6.2%) 0 1 (3.4%)
Initial rhythm
AESP 1 (6.2%) 0 1 (3.4%)
Sinus bradycardia 1 (6.2%) 0 1 (3.4%)
Atrial fibrillation 4 (25%) 1 (7.1%) 0
Indeterminate rhythm 1 (6.2%) 0 0
Sinus rhythm 7 (43.8%) 12 (85.7%) 26 (89.7%)
Sinus tachycardia 2 (12.5%) 1 (7.1%) 1 (3.4%)
Abnormal ECG findings 12 (75%) 8 (57.1%) 21 (72.4%)

Discussion

This study describes the frequency of electrocardiographic changes in patients related to the severity of hyperkalemia and the occurrence of clinical outcomes. Over half of the cases exhibited at least one abnormal finding with the highest proportion in the moderate hyperkalemia group. The most common finding was peaked T wave followed by wide QRS. Variables such as age, CKD, and peaked T wave were statistically significant with the severity. The most frequently reported symptom was weakness. The mild hyperkalemia group had the highest percentage of mortality.

In our study, the most common finding was peaked T wave, followed by wide QRS with bizarre morphologies, prolonged PR interval, and cardiac block rhythm. Previous studies have established the utility of ECG in diagnosing hyperkalemia. Some authors have reported that the ECG exhibits low sensitivity and specificity,4 but the sensitivity increased in patients with serum potassium ≥6 mEq/l.19,20,26–28

Fordjour et al reported that 50% of patients with potassium ≥6.5 meq/L exhibited abnormal ECG results, and the most common finding was the peaked T wave and conduction abnormalities, including prolonged first-degree AV block and QRS.29 Other studies have reported peaked T wave with percentages until 34%.5,30 Our findings indicated that the peaked T wave was the most prevalent electrocardiographic abnormality in all groups of severity suggesting its increased frequency with the severity of hyperkalemia according to the literature. Recent study has indicated that the T-wave did not significantly correlate to serum potassium levels, and its application in clinical practice could be limited.11 However, our results demonstrate statistical significance between the peaked T wave and severity, with a probability of up to 2 times more likely to have this electrocardiographic finding with increased severity.

Heart block rhythm has been documented in several case reports in patients with high serum potassium level which describe AV block or branch block AV node’s susceptibility to hyperkalemia.31–33 Varga et al described AV block in moderate (n: 10/97) and severe (n: 7/38).13 This finding is more common in severe hyperkalemia. However, the number of patients with this finding in our population was high and could be related to cardiovascular comorbidities.

In CKD group, the interpretation of the ECG could be less specific. Fluctuations in the serum calcium concentration due to exogenous substitution with oral calcium, vitamin D supplementation, and treatment with a dialysate contribute to a higher calcium threshold. This condition could be a cardio-protective factor stabilizing the transmembrane potential. This may explain a greater tolerance to hyperkalemia and fewer abnormal changes in the ECGG.34,35

Mulia et al described the most common ECG abnormalities were the prolonged QTc interval (36.6%), fragmented QRS complex (29.8%), poor R wave progression (24.6%), and peaked T wave (22%).27 Powell et al demonstrated no difference in ECG changes between acute and chronic hyperkalemic groups. This study concluded that increasing age, higher potassium levels, and prior ischemic heart disease predisposed patients to ECG changes, although pharmacologic calcium is known to protect against hyperkalemic arrhythmias.36

A recent study showed that a QRS duration of ≥120 ms was the most predictive factor for hyperkalemia in the End-Stage Renal Disease population.37 Thus, the absence of electrocardiographic changes in patients with hyperkalemia undergoing hemodialysis must be interpreted carefully.14 In our study, the ECG abnormalities related to hyperkalemia in patients with CKD were above 60%. Peaked T wave and Wide QRS with bizarre morphologies were the most common abnormal ECG findings in the population with CKD. These results are similar to the previous articles cited. Due to these patients exhibiting diverse electrocardiographic findings, it becomes a challenge to characterize them.

Regarding treatment, the use of loop diuretics, beta-agonists, polarizing solutions, hemodialysis, insulin, and ion-exchange resins with an action potential stabilizer membrane with calcium gluconate has been described.31,37 The alternatives in the treatments are associated with the severity of hyperkalemia, comorbidities, and chronicity.

Insulin/Glucose and Loop Diuretics were the most common treatments in our study. However, most patients received combined therapies, making it impossible to assess the individual efficacy of each of these. Nevertheless, we did not compare the interventions to establish which drug is more effective in reducing potassium levels.

Hyperkalemia is an independent risk factor to increase mortality, cardiovascular events, ≥hospitalizations, and ICU admissions. Cai et al determined that hyperkalemia increases the 90-day mortality in patients with acute and chronic renal disease.38 Goyal et al reported intra-hospital mortality in 61% of patients with serum potassium levels ≥5.5 6 mEq/l.39 In our study, the intra-hospital death was 11%, and the mild hyperkalemia group had the higher mortality. One of the potential reasons why the mild hyperkalemia group exhibited higher mortality was associated with age, given that over 90% were aged 60 or older, in contrast to 79% in the more severe group. Another possible explanation was the initial electrocardiographic rhythm, as 56% in the mild severity group showed rhythm abnormalities compared to only 10% in the more severe group. Although both groups had a diagnosis related to infectious disease, there was a higher proportion of patients in the mild hyperkalemia group.

One of the strengths of this study is that it represents a large amount of the population of southwestern Colombia and that until now has not been reported in our region. However, upon reviewing the literature, we found no reported studies in our country with the number of patients comparable to ours. While case reports exist, none provides a detailed description of multiple cases. Despite the existing literature, there is a lack of a comprehensive description of our specific population, hindering the proposal of new hypotheses. Consequently, we aim to present our work, compiling the experiences from this highly complex university hospital leading institution in the Southwest of Colombia. Although our findings align with the literature described previously, we believe it is crucial to address potential future research questions emerging from this study.

This study encompasses a significant number of patients, contributing to the description of the most common findings in the population with hyperkalemia in an emergency department. A more detailed characterization of patients with chronic kidney disease is required to yield additional results of interest.

Conclusion

The high serum potassium levels could cause abnormal ECG findings. However, the severity of hyperkalemia did not consistently exhibit abnormal ECG findings. Age may act as a factor inversely proportional to severity, contrary to what is evident in patients with Chronic Kidney Disease (CKD). Specifically regarding the T wave, it is more commonly observed in patients with moderate and severe hyperkalemia. Therefore, it is imperative to exercise caution in the ECG report, especially in patients with high serum levels of potassium as a chronic or acute kidney disease. Comparative studies to elucidate these findings are necessary.

Funding Statement

There is no funding to report.

Data Sharing Statement

The data that support the findings of this study are available from Fundación Valle del Lili but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the corresponding author upon reasonable request and with permission of Fundación Valle del Lili.

Ethics Approval and Consent to Participate

The Biomedical Research Ethics Committee at the University Hospital (Comité de Ética en Investigación Biomédica de la Fundación Valle del Lili) approved this study (Approved No. 280-2021, No. 15 of July 28, 2021). This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. This study adhered to the standards of the STROBE guidelines. The researchers did not expose the patients to biological, psychological, or social risks. Therefore, the ethics committee approved the waiver of informed consent.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16(6):1–14. doi: 10.1186/cc11872 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical Management of Hyperkalemia. Mayo Clin Proc. 2021;96(3):744–762. doi: 10.1016/j.mayocp.2020.06.014 [DOI] [PubMed] [Google Scholar]
  • 3.Littmann L, Gibbs MA. Electrocardiographic manifestations of severe hyperkalemia. J Electrocardiol. 2018;51(5):814–817. doi: 10.1016/j.jelectrocard.2018.06.018 [DOI] [PubMed] [Google Scholar]
  • 4.Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3(2):324–330. doi: 10.2215/CJN.04611007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Long B, Warix JR, Koyfman A. Controversies in Management of Hyperkalemia. J Emerg Med. 2018;55(2):192–205. doi: 10.1016/j.jemermed.2018.04.004 [DOI] [PubMed] [Google Scholar]
  • 6.Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28(11):3155–3165. doi: 10.1681/ASN.2016121344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Alfonzo A, Harrison A, Baines R, Chu A, Mann S, et al. Clinical practice guidelines: Treatment of acute hyperkalaemia in adults. The UK Kidney Association (UKKA). England. 2020. [Google Scholar]
  • 8.Nakhoul GN, Huang H, Arrigain S, et al. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2015;41(6):456–463. PMID: 26228532; PMCID: PMC4686260. doi: 10.1159/000437151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Naumann M, Reiners K, Schalke B, Schneider C. Hyperkalaemia mimicking acute Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1994;57(11):1436–1437. PMID: 7964831; PMCID: PMC1073207. doi: 10.1136/jnnp.57.11.1436-a [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Evers S, Engelien A, Karsch V, Hund M. Secondary hyperkalaemic paralysis. J Neurol Neurosurg Psychiatry. 1998;64(2):249–252. PMID: 9489541; PMCID: PMC2169962. doi: 10.1136/jnnp.64.2.249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yoon D, Lim HS, Jeong JC, et al. Quantitative evaluation of the relationship between t-wave-based features and serum potassium level in real-world clinical practice. Biomed Res Int. 2018;2018. doi: 10.1155/2018/3054316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kim YM, Park JE, Hwang SY, et al. Association between wide QRS pulseless electrical activity and hyperkalemia in cardiac arrest patients. Am J Emerg Med. 2021;45:86–91. doi: 10.1016/j.ajem.2021.02.024 [DOI] [PubMed] [Google Scholar]
  • 13.Varga C, Kálmán Z, Szakáll A, et al. ECG abnormalities suggestive of hyperkalemia in normokalemic versus hyperkalemic patients. BMC Emerg Med. 2019;19(1):1–9. doi: 10.1186/s12873-019-0247-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gogas BD, Iliodromitis EK, Leftheriotis DI, Flevari PG, Rallidis LS, Kremastinos DT. Instantaneous electrocardiographic changes and transient sinus rhythm restoration in severe hyperkalaemia. Int J Cardiol. 2011;148(2):e40–2. doi: 10.1016/j.ijcard.2009.05.004 [DOI] [PubMed] [Google Scholar]
  • 15.Rafique Z, Aceves J, Espina I, Peacock F, Sheikh-Hamad D, Kuo D. Can physicians detect hyperkalemia based on the electrocardiogram? Am J Emerg Med. 2020;38(1):105–108. doi: 10.1016/j.ajem.2019.04.036 [DOI] [PubMed] [Google Scholar]
  • 16.Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8):917–924. doi: 10.1001/archinte.158.8.917 [DOI] [PubMed] [Google Scholar]
  • 17.Regolisti G, Maggiore U, Greco P, et al. Electrocardiographic T wave alterations and prediction of hyperkalemia in patients with acute kidney injury. Intern Emerg Med. 2020;15(3):463–472. doi: 10.1007/s11739-019-02217-x [DOI] [PubMed] [Google Scholar]
  • 18.Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18(6):721–729. doi: 10.1053/ajem.2000.7344 [DOI] [PubMed] [Google Scholar]
  • 19.Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113:585–591. doi: 10.1016/j.phrs.2016.09.039 [DOI] [PubMed] [Google Scholar]
  • 20.Durfey N, Lehnhof B, Bergeson A, et al. Severe hyperkalemia: can the electrocardiogram risk stratify for short-term adverse events? West J Emerg Med. 2017;18(5):963–971. doi: 10.5811/westjem.2017.6.33033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Martinez-Vea A, Bardaji A, Garcia C, Oliver JA. Severe hyperkalemia with minimal electrocardiographic manifestations: a report of seven cases. J Electrocardiol. 1999;32:45–49. doi: 10.1016/S0022-0736(99)90020-1 [DOI] [PubMed] [Google Scholar]
  • 22.Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant. 2002;17(9):1639–1642. doi: 10.1093/ndt/17.9.1639 [DOI] [PubMed] [Google Scholar]
  • 23.McIntyre WF, Femenía F, Arce M, Pérez-Riera AR, Baranchuk A. Importance of early electrocardiographic recognition and timely management of hyperkalemia in geriatric patients. Exp Clin Cardiol. 2011;16(2):47–50. [PMC free article] [PubMed] [Google Scholar]
  • 24.Valencia CA, Chacón JA, Jiménez JI. Hiperpotasemia secundaria a uso combinado de un IECA o ARA II con espironolactona. Rev Nefrol Dial Traspl. 2023;43(4):228–235. [Google Scholar]
  • 25.The Renal Association. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. United Kingdom Kidney Association; 2020.
  • 26.Wrenn KD, Slovis CM, Slovis BS. The ability of physicians to predict hyperkalemia from the ECG. Ann Emerg Med. 1991;20(11):1229–1232. doi: 10.1016/S0196-0644(05)81476-3 [DOI] [PubMed] [Google Scholar]
  • 27.Rafique Z, Hoang B, Mesbah H, et al. Hyperkalemia and electrocardiogram manifestations in end-stage renal disease. Int J Environ Res Public Health. 2022;19(23):16140. doi: 10.3390/ijerph192316140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dillon JJ, DeSimone CV, Sapir Y, et al. Noninvasive potassium determination using a mathematically processed ECG: proof of concept for a novel “bloodless, blood test. J Electrocardiol. 2015;48:12–18. doi: 10.1016/j.jelectrocard.2014.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014;347:93–100. doi: 10.1097/MAJ.0b013e318279b105 [DOI] [PubMed] [Google Scholar]
  • 30.Freeman K, Feldman JA, Mitchell P, et al. Effects of presentation and electrocardiogram on time to treatment of hyperkalemia. Acad Emerg Med. 2008;15(3):239–249. doi: 10.1111/j.1553-2712.2008.00058.x [DOI] [PubMed] [Google Scholar]
  • 31.Chandok T, Lee S, Ali N, et al. Dynamic Changes of EKG by severe hyperkalemia: transient left bundle branch block. Cureus. 2023;15(3):2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kosovali BD, Yildiz H. Reversible complete atrioventriculer block in patient with mild hyperkalemia. J Cardiol Curr Res. 2018;11(1):00365. [Google Scholar]
  • 33.Hasnie AA, Baniahmad O, Tolwani A, McElderry HT, Prabhu SD. Complete heart block without ventricular escape secondary to hyperkalemia induced by herbal tea. Heart Rhythm Case Rep. 2021;8(1):45–49. doi: 10.1016/j.hrcr.2021.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mulia EPB, Nugraha RA, A’yun MQ. Electrocardiographic abnormalities among late-stage non-dialysis chronic kidney disease patients. J Basic Clin Physiol Pharmacol. 2021;32(3):155–162. doi: 10.1515/jbcpp-2020-0068 [DOI] [PubMed] [Google Scholar]
  • 35.Powell J, Karabon PJ, Berman AD, Kellerman PS Electrocardiographic manifestations of acute vs chronic hyperkalemia. Abstract of a presentation at the American Society of Nephrology Kidney Week 2019 (Abstract TH-OR068), Washington, DC; 2019.
  • 36.Wu Y, Fu YY, Zhu HD, Xu J, Walline JH. Treatment of hyperkalemic emergencies. World J Emerg Med. 2022;13(3):232–236. doi: 10.5847/wjem.j.1920-8642.2022.054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep. 2019;4(9):1248–1260. doi: 10.1016/j.ekir.2019.05.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cai JJ, Wang K, Jiang HQ, Han T. Characteristics, risk factors, and adverse outcomes of hyperkalemia in acute-on-chronic liver failure patients. Biomed Res Int. 2019;2019:6025726. doi: 10.1155/2019/6025726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307(2):157–164. doi: 10.1001/jama.2011.1967 [DOI] [PubMed] [Google Scholar]

Articles from Open Access Emergency Medicine : OAEM are provided here courtesy of Dove Press

RESOURCES